AHL Partners’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

AHL Partners’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-11,653	Closed	-$138K	–	1438
2017 Q3	$138K	Buy	+11,653	New	+$131K	﹤0.01%	1216

Other funds holding SCMP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

AHL Partners's SCMP Position: Q4 2017 in Review

AHL Partners sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 11,653 shares — an estimated $138K sold.

AHL Partners first reported a position in SCMP in Q3 2017 and held it in 1 quarter. The position peaked at $138K in Q3 2017. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

AHL Partners reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 11,653 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $138K.
AHL Partners first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
AHL Partners's Sucampo Pharmaceuticals, Inc. position peaked at $138K in Q3 2017.
188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.